EMAP II Inhibitors to Treat Cardiovascular Disease
- Detailed Technology Description
- TechnologySummary: Targets Endothelial Monocyte Activating Polypeptide (EMAP II) to promote cardiac tissue regeneration in patients suffering from myocardial infarction or pulmonary hypertension.
- Countries
- United States
- Application No.
- 7,537,757
- *Abstract
-
Background: Cardiovascular disease is the leading cause of mortality in the United States, causing 41 percent of all deaths. Following coronary artery occlusion, myocardial recovery depends on the heart’s ability to develop collateral circulation and revascularize the infarcted myocardium.
Growth factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) promote myocardial revascularization following myocardial infarction. But while much is known about these factors, little is known regarding the molecular mechanisms that counteract these stimuli.
EMAP II is an anti-angiogenic factor in tumor vascular development and could be a negative modulator of lung vascular growth.
TechnologyDescription: Provides methods of facilitating vascular growth in cardiac muscle by inhibiting EMAP II. This is important for patients afflicted with myocardial ischemia, atherosclerosis and other myocardial diseases, such as cardiopathy or cardiac hypertrophy.
Pre-clinical data using an anti-EMAP II antibody suggest therapeutic benefits to this approach. In preclinical animal studies, the cardiac muscle structure and function of treated animals showed significantly reduced damage and improved cellular regeneration after infarction.
Benefits of EMAP II inhibition also have been shown in an animal model of pulmonary hypertension by using an EMAP II receptor antagonist. This treatment has been shown to reduce the distal pulmonary vessel thickening.
Applications:- Myocardial infarction
- Pulmonary hypertension
Advantages:- Provides an alternate target to VEGF or bFGF for promoting cardiac tissue regeneration
Development Stage:- Preclinical data
IP Protection: US Patent 6,306,612; US Patent 6,857,749; US patent 7,264,803; pending US and foreign applications
- *IP Issue Date
- May 25, 2009
- *IP Type
- Other Patent
- Country/Region
- USA
